Earnings ·
Alumis Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $142.2 million…
ALMSAlumis Inc.
Alumis Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $142.2 million compared to net income of $59.3 million in the prior year period. The company held cash and marketable securities of $502.3 million as of June 30, 2026, which management expects will fund operations into the fourth quarter of 2027. Operating expenses included a $41.8 million impairment loss related to the lonigutamab program following a decision to explore strategic alternatives for the asset. R&D expenses decreased to $85.3 million from $108.8 million, while G&A expenses fell to $23.4 million from $34.5 million. The company remains on track to submit an NDA for envudeucitinib in plaque psoriasis in Q4 2026 and anticipates Phase 2b LUMUS data for SLE in Q3 2026. Alumis Inc. is a late-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases.